14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026
VRAX vs REVB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 17, 2026, Revelation Biosciences, Inc. (REVB) captures the overall head-to-head institutional edge over Virax Biolabs Group Limited (VRAX) on higher Unified Composite conviction (34.4/100 SELL vs. 41.7/100 SELL) after splitting the core matrix 4–4 (led by Valuation Multiples), while VRAX wins 3–1 across the 6-pillar growth and valuation breakdown. VRAX trades at $0.43 (N/M Forward P/E, -51515.2% operating margin) versus REVB at $3.83 (0.9x Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While VRAX currently prints a higher short-term Unified Composite Score (41.7/100 SELL vs. REVB 34.4/100 SELL), REVB captures the overall institutional head-to-head verdict (4–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -51515.2% operating margin) and revenue trajectory (+0.0% vs. +684.9% YoY).
Defensive Composite Rating Caution: Although REVB compares more favorably head-to-head, both VRAX (41.7/100 SELL) and REVB (34.4/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
Technical & Structure Timing Caution: VRAX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 18.9); meanwhile REVB trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 58.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on VRAX vs REVB. Trailing 12-month operating profitability (VRAX -51515.2% vs REVB 0.0%) and valuation multiples (VRAX N/M vs REVB 0.9x Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $2.4M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ VRAX vs REVB Key Questions & Quantitative Answers
As of Nov 17, 2026, Revelation Biosciences, Inc. (REVB) captures the overall head-to-head institutional edge over Virax Biolabs Group Limited (VRAX) on higher Unified Composite conviction (34.4/100 SELL vs. 41.7/100 SELL) after splitting the core matrix 4–4 (led by Valuation Multiples), while VRAX wins 3–1 across the 6-pillar growth and valuation breakdown. VRAX trades at $0.43 (N/M Forward P/E, -51515.2% operating margin) versus REVB at $3.83 (0.9x Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While VRAX currently prints a higher short-term Unified Composite Score (41.7/100 SELL vs. REVB 34.4/100 SELL), REVB captures the overall institutional head-to-head verdict (4–4 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. -51515.2% operating margin) and revenue trajectory (+0.0% vs. +684.9% YoY). Defensive Composite Rating Caution: Although REVB compares more favorably head-to-head, both VRAX (41.7/100 SELL) and REVB (34.4/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: VRAX is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 18.9); meanwhile REVB trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 58.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
VRAX leads the Growth & Scale pillar: VRAX posts +684.9% YoY revenue growth and +0.0% YoY earnings growth on $12,423 TTM revenue (61.9% gross margin, -51515.2% operating margin), compared with REVB at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, VRAX generates $12,423 in USD-normalized revenue versus N/A for REVB. In operating R&D and SG&A reinvestment, VRAX deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for REVB.
REVB screens cheaper on headline valuation multiples. VRAX trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 66.3x EV/Revenue (unreported EBITDA margin), whereas REVB trades at 0.9x Forward P/E, 0.9x Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against VRAX (-78.6% ROE) versus REVB (-133.4% ROE) capital efficiency.
In options market volatility and institutional positioning, VRAX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-9.42β · 161% Vol realized risk). By comparison, REVB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (2.97β · 2364% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.